Justin R Lenhard1,2, Visanu Thamlikitkul3, Fernanda P Silveira4, Samira M Garonzik1, Xun Tao5, Alan Forrest1,6, Beom Soo Shin7, Keith S Kaye8, Jürgen B Bulitta5, Roger L Nation9, Jian Li9, Brian T Tsuji1,10. 1. Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences and School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA. 2. California Northstate University College of Pharmacy, Elk Grove, CA, USA. 3. Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 4. Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 5. Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA. 6. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 7. School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, Korea. 8. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA. 9. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. 10. Veterans Administration Western New York Healthcare System, Buffalo, NY, USA.
Abstract
Objectives: The emergence of polymyxin resistance threatens to leave clinicians with few options for combatting drug-resistant Acinetobacter baumannii . The objectives of the current investigation were to define the in vitro emergence of polymyxin resistance and identify a combination regimen capable of eradicating A. baumannii with no apparent drug susceptibilities. Methods: Two clonally related, paired, A. baumannii isolates collected from a critically ill patient who developed colistin resistance while receiving colistin methanesulfonate in a clinical population pharmacokinetic study were evaluated: an A. baumannii isolate collected before (03-149.1, polymyxin-susceptible, MIC 0.5 mg/L) and an isolate collected after (03-149.2, polymyxin-resistant, MIC 32 mg/L, carbapenem-resistant, ampicillin/sulbactam-resistant). Using the patient's unique pharmacokinetics, the patient's actual regimen received in the clinic was recreated in a hollow-fibre infection model (HFIM) to track the emergence of polymyxin resistance against 03-149.1. A subsequent HFIM challenged the pan-resistant 03-149.2 isolate against polymyxin B, meropenem and ampicillin/sulbactam alone and in two-drug and three-drug combinations. Results: Despite achieving colistin steady-state targets of an AUC 0-24 >60 mg·h/L and C avg of >2.5 mg/L, colistin population analysis profiles confirmed the clinical development of polymyxin resistance. During the simulation of the patient's colistin regimen in the HFIM, no killing was achieved in the HFIM and amplification of polymyxin resistance was observed by 96 h. Against the polymyxin-resistant isolate, the triple combination of polymyxin B, meropenem and ampicillin/sulbactam eradicated the A. baumannii by 96 h in the HFIM, whereas monotherapies and double combinations resulted in regrowth. Conclusions: To combat polymyxin-resistant A. baumannii , the triple combination of polymyxin B, meropenem and ampicillin/sulbactam holds great promise.
Objectives: The emergence of polymyxin resistance threatens to leave clinicians with few options for combatting drug-resistant Acinetobacter baumannii . The objectives of the current investigation were to define the in vitro emergence of polymyxin resistance and identify a combination regimen capable of eradicating A. baumannii with no apparent drug susceptibilities. Methods: Two clonally related, paired, A. baumannii isolates collected from a critically ill patient who developed colistin resistance while receiving colistin methanesulfonate in a clinical population pharmacokinetic study were evaluated: an A. baumannii isolate collected before (03-149.1, polymyxin-susceptible, MIC 0.5 mg/L) and an isolate collected after (03-149.2, polymyxin-resistant, MIC 32 mg/L, carbapenem-resistant, ampicillin/sulbactam-resistant). Using the patient's unique pharmacokinetics, the patient's actual regimen received in the clinic was recreated in a hollow-fibre infection model (HFIM) to track the emergence of polymyxin resistance against 03-149.1. A subsequent HFIM challenged the pan-resistant 03-149.2 isolate against polymyxin B, meropenem and ampicillin/sulbactam alone and in two-drug and three-drug combinations. Results: Despite achieving colistin steady-state targets of an AUC 0-24 >60 mg·h/L and C avg of >2.5 mg/L, colistin population analysis profiles confirmed the clinical development of polymyxin resistance. During the simulation of the patient's colistin regimen in the HFIM, no killing was achieved in the HFIM and amplification of polymyxin resistance was observed by 96 h. Against the polymyxin-resistant isolate, the triple combination of polymyxin B, meropenem and ampicillin/sulbactam eradicated the A. baumannii by 96 h in the HFIM, whereas monotherapies and double combinations resulted in regrowth. Conclusions: To combat polymyxin-resistant A. baumannii , the triple combination of polymyxin B, meropenem and ampicillin/sulbactam holds great promise.
Authors: Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki Journal: Clin Infect Dis Date: 2013-05-22 Impact factor: 9.079
Authors: Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji Journal: J Antimicrob Chemother Date: 2016-09-15 Impact factor: 5.790
Authors: Justin R Lenhard; Tanya Brown; Michael J Rybak; Calvin J Meaney; Nicholas B Norgard; Zackery P Bulman; Daniel A Brazeau; Steven R Gill; Brian T Tsuji Journal: Antimicrob Agents Chemother Date: 2015-12-28 Impact factor: 5.191
Authors: S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation Journal: Antimicrob Agents Chemother Date: 2011-05-09 Impact factor: 5.191
Authors: Roger L Nation; Samira M Garonzik; Jian Li; Visanu Thamlikitkul; Evangelos J Giamarellos-Bourboulis; David L Paterson; John D Turnidge; Alan Forrest; Fernanda P Silveira Journal: Clin Infect Dis Date: 2015-11-25 Impact factor: 9.079
Authors: Mohd Hafidz Mahamad Maifiah; Soon-Ee Cheah; Matthew D Johnson; Mei-Ling Han; John D Boyce; Visanu Thamlikitkul; Alan Forrest; Keith S Kaye; Paul Hertzog; Anthony W Purcell; Jiangning Song; Tony Velkov; Darren J Creek; Jian Li Journal: Sci Rep Date: 2016-02-29 Impact factor: 4.379
Authors: David A Butler; Mark Biagi; Xing Tan; Samah Qasmieh; Zackery P Bulman; Eric Wenzler Journal: Curr Infect Dis Rep Date: 2019-11-16 Impact factor: 3.725
Authors: Michael Maynard; G L Drusano; Michael Vicchiarelli; Weiguo Liu; Jenny Myrick; Jocelyn Nole; Brandon Duncanson; David Brown; Arnold Louie Journal: Antimicrob Agents Chemother Date: 2021-07-16 Impact factor: 5.191